Contracts › HT942525FE074
HT942525FE074: Combined Long Term Efferocytosis and Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity Response Hiv Vaccine Clinical Trial to Investigate Safety and Immunogenicity of New Vaccine Candidates in Support of the War Fighter.
Awarded to Laulima Government Solutions, Llc by Defense Health Agency.
$1.2Mobligated
$1.2Mpotential value
29 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HT942525FE074 |
|---|---|
| Vehicle | W81XWH19D0011 |
| Awardee | Laulima Government Solutions, Llc |
| Awarding agency | Defense Health Agency |
| Awarding office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | R405 Support- Professional: Operations Research/Quantitative Analysis |
| Place of performance | MD |
| Period of performance | 30 September 2025 to 29 September 2027 |
| Potential end | 29 September 2027 |
| Estimated recompete solicitation | ~Q2 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record